Bluebird bio, Inc.
BLUE
Clasificación en acciones
#15674
bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery,... bluebird bio, Inc. is a biotechnology firm that concentrates on the discovery, development, and commercialization of innovative gene therapies. These pioneering treatments are aimed at debilitating genetic conditions. Among its leading investigational therapies for severe inherited diseases are betibeglogene autotemcel (beti-cel), intended for patients with transfusion-dependent beta-thalassemia; lovotibeglogene autotemcel (lovo-cel), which targets sickle cell disease (SCD); and elivaldogene autotemcel (eli-cel), developed to address cerebral adrenoleukodystrophy. The company's robust clinical trial program is actively evaluating the safety and efficacy of these treatments. Specifically, lovo-cel's impact on SCD patients is being assessed in studies HGB-205, HGB-206, and HGB-210. Concurrently, beti-cel is under investigation for beta-thalassemia in trials HGB-204, HGB-205, HGB-207, and HGB-212. Furthermore, bluebird bio maintains strategic collaborations and licensing arrangements with entities such as Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company, which began its operations in 1992, was formerly known as Genetix Pharmaceuticals, Inc., and rebranded as bluebird bio, Inc. in September 2010. Its principal office is located in Cambridge, Massachusetts.
Precio por acción
$4.97
Última sincronización: 2025-06-02
Capitalización bursátil
$318.62M
Cambio (1 día)
0.00%
Cambio (1 año)
-38.03%
País
US
Comercio Bluebird bio, Inc. (BLUE)
Categoría
Healthcare
Capitalización de mercado de Bluebird bio, Inc.(BLUE)
Capitalización bursátil: $318.62M
A fecha de October 2026, Bluebird bio, Inc. tiene una capitalización de mercado de $318.62M. Esto convierte a Bluebird bio, Inc. en la 15674th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Bluebird bio, Inc. desde 2018 hasta 2026
BLUE en comparación con los más populares 5 títulos stocks
